Skip to main content
SpringerLink
Log in

CDK-4/-6 inhibitors + letrozole cost effective for HR+/HER2- metastatic breast cancer?

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Masurkar PP, et al. Cost-effectiveness of CDK4/6 inhibitors in the first-line treatment of HR+/HER2- metastatic breast cancer in postmenopausal women in the United States. 112th Annual Meeting of the American Association for Cancer Research : abstr. 891, 10 Apr 2021. Available from: URL: https://www.abstractsonline.com/pp8/#!/9325/presentation/1928

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

CDK-4/-6 inhibitors + letrozole cost effective for HR+/HER2- metastatic breast cancer?. PharmacoEcon Outcomes News 879, 7 (2021). https://doi.org/10.1007/s40274-021-7730-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-7730-z

Search

Navigation